Chugai Pharmaceutical Co., Ltd. (CHGCF)

Market Cap	69.27B
Revenue (ttm)	7.97B
Net Income (ttm)	2.70B
Shares Out	n/a
EPS (ttm)	1.64
PE Ratio	25.64
Forward PE	n/a
Dividend	0.26 (0.60%)
Ex-Dividend Date	Jun 27, 2024

Volume	881
Average Volume	8,773
Open	40.21
Previous Close	42.42
Day's Range	40.21 - 40.21
52-Week Range	29.04 - 50.31
Beta	0.50
RSI	44.86
Earnings Date	Jan 30, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,604
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCF

Financial Performance

In 2023, Chugai Pharmaceutical's revenue was 1.11 trillion, a decrease of -11.79% compared to the previous year's 1.26 trillion. Earnings were 325.47 billion, a decrease of -13.08%.

Financial numbers in JPY